Olmiwake-Trio Tablet is a combination antihypertensive medication containing Olmesartan Medoxomil (40 mg), Cilnidipine (10 mg), and Chlorthalidone (12.5 mg). Olmesartan Medoxomil is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Cilnidipine is a calcium channel blocker of the dihydropyridine class that inhibits L-type and N-type calcium channels, resulting in vasodilation and reduced peripheral vascular resistance. Chlorthalidone is a thiazide-like diuretic that promotes sodium and water excretion by inhibiting sodium reabsorption in the distal convoluted tubules, thereby reducing plasma volume and blood pressure. The synergistic action of these three agents provides effective management of hypertension, improving blood pressure control in patients inadequately responsive to monotherapy. Olmiwake-Trio Tablet is indicated for the treatment of essential hypertension and may reduce the risk of cardiovascular events associated with elevated blood pressure. It should be used under medical supervision, with regular monitoring of blood pressure, renal function, and electrolytes to minimize potential adverse effects such as hypotension, electrolyte imbalance, and renal impairment. Patient adherence and lifestyle modifications are essential for optimal therapeutic outcomes.